News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Medexus gets Health Canada nod to market tumor imaging material Gleolan for neurosurgery


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 Gleolan is finally approved in Canada.   It has been standard of care in Europe for many years before it was approved in the USA 3 years ago.   According to the article cited , it doubles the chance of a complete resection, and doubles the 6 month progression free survival rate.  This is a dye used at the time of surgery to make it easier for the surgeon to identify where the tumor is.


Posted on: 09/11/2020

Medexus gets Health Canada nod to market tumor imaging material Gleolan for neurosurgery

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740